NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, in Minneapolis, Minnesota. Details for the presentations are as follows: Title: Efficacy of SYMBRAVO® (MoSEIC™ meloxicam and rizatriptan) by Baseline Migraine-Associated Disability: Post-Hoc Analysis of the INTERCEPT TrialLead Author: Stewart Tepper, MD, Clinical Professor of Neurology at the Geisel School of Medicine at Dartmouth and Vice President of the New England Institute for Neurology and HeadachePresentation...

DENVER, June 18, 2025 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today announced it will report financial results for the thirteen week period ended May 31, 2025, on Thursday, July 10, 2025, before market open. The Company will host a conference call to discuss these results with additional comments and details provided at that time. Participating on the call will be Geoff Tanner, President and Chief Executive Officer, and Chris Bealer, incoming Chief Financial Officer effective July 3, 2025. The conference call is scheduled to begin at 6:30 a.m. Mountain time (8:30 a.m. Eastern time) on Thursday, July 10, 2025. Investors interested in participating in the live call can dial 1-877-407-0792...

Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML. Additionally, the Company released a Virtual Investor “What This...

Jiménez’s Victory marks second Tour win for Newton shafts CAMARILLO, Calif., June 18, 2025 (GLOBE NEWSWIRE) — via IBN — NEWTON GOLF Company (Nasdaq: NWTG) (“NEWTON GOLF” or the “Company”), a technology-forward golf company with a growing portfolio of golf products—including putters, golf shafts, golf grips, and other golf-related accessories—announced today that Miguel Ángel Jiménez, one of the most accomplished players on the PGA TOUR champions, has officially signed with the brand and will play its shaft technology moving forward. The multi-time Tour winner validated the partnership immediately by capturing a victory at the Principal Charity Classic using the Newton Fast Motion shaft, introduced in April 2025.  Jimenéz secured his 16th PGA TOUR Champions title with a birdie on the first sudden-death playoff hole, marking...

Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that it is well-tolerated and has a safety profile consistent with the previously completed phase 1 and 2 studies and ongoing phase 1 open-label extension study NEWARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics’ 96-week pivotal phase 3 TransportNPC study evaluating intravenous (IV) Trappsol® Cyclo™ for the potential treatment of Niemann-Pick Disease Type C1 (NPC1) will continue based on the independent Data Monitoring Committee (DMC) review of safety and efficacy data...

Virtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at ESMO GI on July 2, 2025 ROCKVILLE, Md., June 18, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it will host a webinar to recap new givastomig data being presented at ESMO GI 2025, with a key opinion leader (KOL), on Tuesday, July 8, 2025 at 2:00pm EDT. To register, click here. The event will feature Samuel J. Klempner, MD (Associate Professor of Medicine at Massachusetts General Hospital), who will discuss new givastomig data in combination with immunochemotherapy. Givastomig,...

Second commercial delivery underway as part of multi-year contract with leading U.S. healthcare partner Strategic manufacturing upgrades drive scalability, efficiency, and increases capacity to support production growth NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced an update on the execution of its first shipments under the previously announced $50 million SoloGard sales agreement, alongside a series of advanced manufacturing upgrades. Sharps has initiated the second shipment of its first commercial order of SoloGard syringes under a multi-year supply agreement with a U.S.-based leader in IV flushing...

VANCOUVER, British Columbia, June 18, 2025 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSXV: AIS, OTC- PINK: AISSF) (“AIS” or the “Company”) announces that further to the Company’s press release dated February 24, 2025 the Company has settled $380,927.75 of debt through the issuance of an aggregate of 7,618,555 common at a deemed price of $0.05 per Common Share (the “Shares for Debt Transaction”). The Company completed the Shares for Debt Transaction to improve its financial position by reducing its existing liabilities. All securities issued in connection with the Shares for Debt Transaction will be subject to a four-month hold period from the closing date under applicable Canadian securities laws. Under the debt settlement 6,429,480 shares were issued to non-arms length parties in settlement of $321,474. The participation...